Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

被引：32

作者：

Burdett, Nikki L. ^{[1
,2
,3
]}

Willis, Madelynne O. ^{[1
]}

Alsop, Kathryn ^{[1
,2
]}

Hunt, Allison L. ^{[4
,5
,6
]}

Pandey, Ahwan ^{[1
]}

Hamilton, Phineas T. ^{[7
]}

Abulez, Tamara ^{[5
,6
,8
]}

Liu, Xuan ^{[9
]}

Hoang, Therese ^{[1
]}

Craig, Stuart ^{[1
]}

Fereday, Sian ^{[1
,2
]}

Hendley, Joy ^{[1
]}

Garsed, Dale W. ^{[1
,2
]}

Milne, Katy ^{[7
]}

Kalaria, Shreena ^{[7
]}

Marshall, Ashley ^{[7
]}

Hood, Brian L. ^{[5
,6
,8
]}

Wilson, Katlin N. ^{[5
,6
,8
]}

Conrads, Kelly A. ^{[5
,6
,8
]}

Pishas, Kathleen, I ^{[1
,2
]}

Ananda, Sumitra ^{[1
,10
,11
,12
]}

Scott, Clare L. ^{[1
,13
]}

Antill, Yoland ^{[14
,15
,16
]}

McNally, Orla ^{[17
,18
]}

Mileshkin, Linda ^{[1
,2
]}

Hamilton, Anne ^{[1
,2
,17
]}

Au-Yeung, George ^{[1
,2
]}

Devereux, Lisa ^{[1
,2
]}

Thorne, Heather ^{[1
,2
]}

Bild, Andrea ^{[19
]}

Bateman, Nicholas W. ^{[6
,8
,20
]}

Maxwell, G. Larry ^{[4
,5
,6
,20
]}

Chang, Jeffrey T. ^{[9
]}

Conrads, Thomas P. P. ^{[5
,6
,8
,20
]}

Nelson, Brad H. ^{[7
,21
,22
]}

Bowtell, David D. L. ^{[1
,2
]}

Christie, Elizabeth L. L. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

[3] Eastern Hlth, Dept Med Oncol, Box Hill, Vic, Australia

[4] Womens Hlth Integrated Res Ctr, Inova Hlth Syst, Inova Womens Serv Line, Annandale, Vic, Australia

[5] Uniformed Serv Univ Hlth Sci, Gynecol Canc Ctr Excellence, Dept Obstet & Gynecol, Bethesda, MD USA

[6] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA

[7] Deeley Res Ctr, BC Canc, Victoria, BC, Canada

[8] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD USA

[9] Univ Texas Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX USA

[10] Western Hlth, Dept Med Oncol, St Albans, Vic, Australia

[11] Univ Melbourne, Dept Med, Western Hlth, St Albans, Vic, Australia

[12] Epworth Healthcare, East Melbourne, Vic, Australia

[13] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

[14] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia

[15] Cabrini Hlth, Malvern, Vic, Australia

[16] Peninsula Hlth, Dept Med Oncol, Frankston, Vic, Australia

[17] Royal Womens Hosp, Parkville, Vic, Australia

[18] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[19] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Monrovia, CA USA

[20] Uniformed Serv Univ Hlth Sci, John P Murtha Canc Ctr Res Program, Dept Surg, Bethesda, MD USA

[21] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada

[22] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada

来源：

NATURE GENETICS | 2023年 / 55卷 / 03期

基金：

澳大利亚国家健康与医学研究理事会; 加拿大创新基金会; 英国医学研究理事会;

关键词：

CIRCULATING TUMOR DNA; GERMLINE MUTATIONS; EVOLUTIONARY HISTORY; SOMATIC MUTATIONS; PARP INHIBITOR; GENES; RESISTANCE; SIGNATURES; REVERSION; DETERMINANTS;

D O I：

10.1038/s41588-023-01320-2

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC. Patients had polyclonal disease, and several resistance mechanisms were identified within most patients, including reversion mutations and HR restoration by other means. We also observed frequent whole-genome duplication and global changes in immune composition with evidence of immune escape. This analysis highlights diverse evolutionary changes within HGSC that evade therapy and ultimately overwhelm individual patients. Multiple samples collected at autopsy from women with homologous recombination-deficient high-grade serous ovarian cancer highlight substantial inter- and intratumoral heterogeneity. A plethora of resistance mechanisms were identified within and between patients.

引用

页码：437 / +

页数：33

共 50 条

[21] Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer
Parkes, Eileen E.
Kennedy, Richard D.
ONCOLOGIST, 2016, 21 (05) : 586 - 593
[22] Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
Shen, Yen Ting
Wang, Lucy
Evans, James C.
Allen, Christine
Piquette-Miller, Micheline
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)
[23] Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
Gomez, Miriam K.
Illuzzi, Giuditta
Colomer, Carlota
Churchman, Michael
Hollis, Robert L.
O'Connor, Mark J.
Gourley, Charlie
Leo, Elisabetta
Melton, David W.
CANCERS, 2020, 12 (06) : 11 - 14
[24] A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
Kreuzinger, Caroline
Geroldinger, Angelika
Smeets, Dominiek
Braicu, Elena Ioana
Sehouli, Jalid
Koller, Julia
Wolf, Andrea
Darb-Esfahani, Silvia
Joehrens, Korinna
Vergote, Ignace
Vanderstichele, Adriaan
Boeckx, Bram
Lambrechts, Diether
Gabra, Hani
Wisman, G. Bea A.
Trillsch, Fabian
Heinze, Georg
Horvat, Reinhard
Polterauer, Stephan
Berns, Els
Theillet, Charles
Castillo-Tong, Dan Cacsire
CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7621 - 7632
[25] High-grade serous ovarian cancer after bilateral salpingo-oophorectomy
Evans, D. Gareth
Flaum, Nicola
Crosbie, Emma J.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024,
[26] The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Garsed, Dale W.
Pandey, Ahwan
Fereday, Sian
Kennedy, Catherine J.
Takahashi, Kazuaki
Alsop, Kathryn
Hamilton, Phineas T.
Hendley, Joy
Chiew, Yoke-Eng
Traficante, Nadia
Provan, Pamela
Ariyaratne, Dinuka
Au-Yeung, George
Bateman, Nicholas W.
Bowes, Leanne
Brand, Alison
Christie, Elizabeth L.
Cunningham, Julie M.
Friedlander, Michael
Grout, Bronwyn
Harnett, Paul
Hung, Jillian
McCauley, Bryan
McNally, Orla
Piskorz, Anna M.
Saner, Flurina A. M.
Vierkant, Robert A.
Wang, Chen
Winham, Stacey J.
Pharoah, Paul D. P.
Brenton, James D.
Conrads, Thomas P.
Maxwell, George L.
Ramus, Susan J.
Pearce, Celeste Leigh
Pike, Malcolm C.
Nelson, Brad H.
Goode, Ellen L.
DeFazio, Anna
Bowtell, David D. L.
NATURE GENETICS, 2022, 54 (12) : 1853 - 1864
[27] AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
Azzalini, Eros
Tierno, Domenico
Bartoletti, Michele
Barbazza, Renzo
Giorda, Giorgio
Puglisi, Fabio
Cecere, Sabrina Chiara
Losito, Nunzia Simona
Russo, Daniela
Stanta, Giorgio
Canzonieri, Vincenzo
Bonin, Serena
CANCERS, 2022, 14 (02)
[28] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Morgan, Robert D.
Clamp, Andrew R.
Evans, D. Gareth R.
Edmondson, Richard J.
Jayson, Gordon C.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
[29] 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
Hurley, Rachel M.
Hendrickson, Andrea E. Wahner
Visscher, Daniel W.
Ansel, Peter
Harrell, Maria I.
Wagner, Jill M.
Negron, Vivian
Goergen, Krista M.
Maurer, Matthew J.
Oberg, Ann L.
Meng, X. Wei
Flatten, Karen S.
De Jonge, Maja J. A.
Van Herpen, Carla D.
Gietema, Jourik A.
Koornstra, Rutger H. T.
Jager, Agnes
den Hollander, Martha W.
Dudley, Matthew
Shepherd, Stacie P.
Swisher, Elizabeth M.
Kaufmann, Scott H.
GYNECOLOGIC ONCOLOGY, 2019, 153 (01) : 127 - 134
[30] Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L.
Ng, C. K. Y.
Melnyk, N.
Garcia, M. J.
Hardcastle, T.
Temple, J.
Langdon, S.
Huntsman, D.
Brenton, J. D.
ONCOGENE, 2010, 29 (35) : 4905 - 4913

← 1 2 3 4 5 →